✨ Medicines Act Notices
NEW ZEALAND GAZETTE
5 AUGUST
2145
Health
Medicines Act 1981
Consent to the Distribution of Changed Medicines
Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the changed medicines which were referred to the Minister of Health under the provisions of section 24 (5) of the Act and are set out in the Schedule hereto:
Schedule
Product: Omniscan.
Active Ingredient(s): Gadodiamide 287 mg/mL.
Calcium sodium 12 mg/mL.
Dosage Form: Solution for injection.
NZ Sponsor: Nycomed New Zealand Limited.
Manufacturer(s): Nycomed AS Production, Inc., Oslo, Norway.
Nycomed Puerto Rico Inc., Barceloneta, Puerto Rico.
Nycomed Ireland Limited, Carrigtwohill, Co. Cork, Eire.
Dated this 29th day of July 1999.
G. R. BOYD, Chief Advisor, Safety and Regulation (pursuant to delegation given by the Minister of Health on the 20th day of February 1997).
go5637
Provisional Consent to the Distribution of a New Medicine
Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicine set out in the Schedule hereto:
Schedule
Product: Xeloda.
Active Ingredient(s): Capecitabine 150 mg.
Dosage Form: Film coated tablet.
NZ Sponsor: Roche Products (New Zealand) Limited.
Manufacturer(s): Hoffmann-La Roche Inc., Nutley, New Jersey, United States of America.
Product: Xeloda.
Active Ingredient(s): Capecitabine 500 mg.
Dosage Form: Film coated tablet.
NZ Sponsor: Roche Products (New Zealand) Limited.
Manufacturer(s): Hoffmann-La Roche Inc., Nutley, New Jersey, United States of America.
Note: This consent is valid for 2 years from the date of publication of this notice.
Dated this 29th day of July 1999.
G. R. BOYD, Chief Advisor, Safety and Regulation (pursuant to delegation given by the Minister of Health on the 20th day of February 1997).
go5639
Consent to the Distribution of a New Medicine
Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicine set out in the Schedule hereto:
Schedule
Product: Eryhexal.
Active Ingredient(s): Erythromycin ethylsuccinate 4.935 g.
Dosage Form: Powder for oral suspension.
NZ Sponsor: Hexal New Zealand Pty Limited.
Manufacturer(s): Allphamed PHARBIL Arzneimittel GmbH, Göttingen, Germany.
Product: Eryhexal.
Active Ingredient(s): Erythromycin ethylsuccinate 11.838 g.
Dosage Form: Powder for oral suspension.
NZ Sponsor: Hexal New Zealand Pty Limited.
Manufacturer(s): Allphamed PHARBIL Arzneimittel GmbH, Göttingen, Germany.
Next Page →
PDF embedding disabled (Crown copyright)
View this page online at:
VUW Te Waharoa —
NZ Gazette 1999, No 90
NZLII —
NZ Gazette 1999, No 90
✨ LLM interpretation of page content
🏥 Consent to the Distribution of Changed Medicines
🏥 Health & Social Welfare29 July 1999
Medicines Act 1981, Consent, Changed Medicines, Omniscan, Gadodiamide
- G. R. Boyd, Chief Advisor, Safety and Regulation
🏥 Provisional Consent to the Distribution of a New Medicine
🏥 Health & Social Welfare29 July 1999
Medicines Act 1981, Provisional Consent, New Medicine, Xeloda, Capecitabine
- G. R. Boyd, Chief Advisor, Safety and Regulation
🏥 Consent to the Distribution of a New Medicine
🏥 Health & Social Welfare29 July 1999
Medicines Act 1981, Consent, New Medicine, Eryhexal, Erythromycin ethylsuccinate
- G. R. Boyd, Chief Advisor, Safety and Regulation